Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
IPO Year: 1992
Exchange: NASDAQ
Website: gilead.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/19/2025 | $128.00 | Neutral → Outperform | Daiwa Securities |
| 8/8/2025 | $127.00 | Hold → Buy | Truist |
| 7/25/2025 | $133.00 | Hold → Buy | Needham |
| 4/22/2025 | $125.00 | Overweight | Cantor Fitzgerald |
| 3/4/2025 | $115.00 → $132.00 | Outperform | Oppenheimer |
| 2/18/2025 | $120.00 | Hold → Buy | Deutsche Bank |
| 2/13/2025 | $108.00 | Hold → Buy | DZ Bank |
| 1/10/2025 | $87.00 → $113.00 | Equal-Weight → Overweight | Morgan Stanley |
| 12/10/2024 | $109.00 | Buy | BofA Securities |
| 11/15/2024 | $110.00 | Outperform | Wolfe Research |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
3 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - GILEAD SCIENCES, INC. (0000882095) (Reporting)
Fastest customizable press release news feed in the world
Gilead Sciences, Inc. (NASDAQ:GILD) today announced the Phase 3 ASCENT-07 study investigating Trodelvy® (sacituzumab govitecan-hziy) versus chemotherapy as a first-line treatment post-endocrine therapy in HR+/HER2-negative metastatic breast cancer patients did not meet the primary endpoint of progression-free survival (PFS) as assessed by Blinded Independent Central Review (BICR) according to RECIST v1.1 criteria. Overall survival is a key secondary endpoint and was not mature at the time of the primary analysis; however, an early trend was observed favoring patients treated with Trodelvy compared to chemotherapy. The ASCENT-07 study will continue to further assess overall survival. "HR+/
– New Data Exclusive to Livdelzi Highlights its Potential as an Effective and Well-Tolerated Option for PBC Patients Switching from Obeticholic Acid – – Analysis of Phase 3 ASSURE Study Finds Livdelzi Shows Promising Data on Liver Stiffness in PBC Patients After 3 Years – – Livdelzi Data in PBC Participants Provide Outcomes for Long-Term Biochemical Response, which Slows Disease Progression and Sustained Reductions in Chronic Itch, which Impacts Patient Wellbeing and Quality of Life – Gilead Sciences, Inc. (NASDAQ:GILD) today announced new long-term data reinforcing the safety and efficacy profile of Livdelzi® (seladelpar) for people living with primary biliary cholangitis (PBC). Finding
Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its executives will be speaking at the following investor conferences: UBS Global Healthcare Conference on Monday, November 10 at 11:00 AM Eastern Time Jefferies Global Healthcare Conference in London on Wednesday, November 19 at 2:00 PM Greenwich Mean Time Citi's Global Healthcare Conference on Tuesday, December 2 at 11:15 AM Eastern Time Annual Evercore Healthcare Conference on Wednesday, December 3 at 10:50 AM Eastern Time The live webcasts can be accessed at the company's investors page at investors.gilead.com. The replays will be available for at least 30 days following the presentation. About Gilead Sciences Gilea
– Updated Results from Phase 2 Pivotal iMMagine-1 Study of Anito-cel for Relapsed/Refractory Multiple Myeloma to be Presented Orally – – New Findings Reinforce Yescarta's® Curative Potential as Second-Line Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma – – Next-Generation CAR T-cell Therapies Suggest High Response Rates and Encouraging Durability in B-Cell Malignancies – Gilead Sciences, Inc. (NASDAQ:GILD) and Kite, a Gilead Company, will present 21 abstracts, including 5 oral presentations, during the 67th American Society of Hematology (ASH) Annual Meeting and Exposition (December 6-9). These data showcase Kite's continued progress in transforming blood cancer ca
Gilead Sciences, Inc. (NASDAQ:GILD) today announced it has been awarded the prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product for Yeztugo® (lenacapavir), the company's twice-yearly injectable HIV-1 capsid inhibitor that provides adults and adolescents (≥35kg) at risk of HIV-1 acquisition with a new, highly effective option for pre-exposure prophylaxis (PrEP) for the prevention of HIV. The award, which recognizes outstanding pharmaceutical products for their contributions to improving human health, is a testament to Gilead's long-standing commitment to HIV innovation. HIV continues to pose a formidable global health challenge, with 1.3 million new infections occurring
Product Sales Excluding Veklury Increased 4% Year-Over-Year to $7.1 billion Biktarvy Sales Increased 6% Year-Over-Year to $3.7 billion Gilead Sciences, Inc. (NASDAQ:GILD) announced today its third quarter 2025 results of operations. "We continue to deliver on Gilead's robust portfolio with a strong start for Yeztugo, rapidly growing uptake of Biktarvy, Descovy and Livdelzi, and positive data for Trodelvy in 1L metastatic triple negative breast cancer," said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. "With multiple potential product launches in 2026, the strongest clinical pipeline in Gilead's history, and no major loss of exclusivity expected until 2036, we are well-
- Late-Breaking Real-World Experience of People Switching from Obeticholic Acid to Livdelzi® to be Presented at The Liver Meeting® 2025 - - New Three-Year Interim Data Demonstrates Livdelzi® May Help Stabilize or Improve Liver Health in PBC Patients - Gilead Sciences, Inc. (NASDAQ:GILD) will present new research that reinforces its commitment to advancing innovation for people living with liver disease at The Liver Meeting® 2025, hosted by the American Association for the Study of Liver Diseases (AASLD), November 7-11 in Washington, D.C. Key findings from more than 35 accepted abstracts across PBC and viral hepatitis will include late-breaking data and three oral presentations. Primar
DIAMOND BAR, Calif., Oct. 21, 2025 /PRNewswire/ -- The Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL)., today announced the appointments of Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners. "I believe Carol and Mehrdad will be exceptional partners to the IFLI team and portfolio as they bring decades of strategic leadership and drug development expertise," said David McCullagh, Man
– LYVDELZI is the Only Medicine to Demonstrate Statistically Significant and Durable Improvements in Both Pruritus and Markers of Cholestasis Related to the Risk of Disease Progression in a Phase 3 Trial – – LYVDELZI Expands Gilead's Long-Standing Commitment to People Living with Liver Disease – MISSISSAUGA, ON, Oct. 21, 2025 /CNW/ - Gilead Sciences, Inc. (NASDAQ:GILD) today announced that Health Canada has approved LYVDELZI (seladelpar) for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate response to UDCA alone, or as monotherapy in patients unable to tolerate UDCA. This market authorization has been iss
– Additional Phase 3 PURPOSE Data Reinforce the Safety Profile of Twice-Yearly Yeztugo® as an Effective HIV Prevention Option Across Diverse Populations – – New Data Show Higher Treatment Satisfaction After Switching from IM CAB+RPV to Biktarvy® – – New Research Reaffirms Veklury® in High-Risk COVID-19 Populations and Obeldesivir in Emerging Pathogens – Gilead Sciences, Inc. (NASDAQ:GILD) will present new findings from its antiviral research and development programs at IDWeek, taking place October 19-22 in Atlanta, GA. Data from 34 presentations across HIV, respiratory viruses, viral hepatitis, and viruses of pandemic potential including six oral presentations underscore Gilead's lead
10-Q - GILEAD SCIENCES, INC. (0000882095) (Filer)
8-K - GILEAD SCIENCES, INC. (0000882095) (Filer)
144 - GILEAD SCIENCES, INC. (0000882095) (Subject)
8-K - GILEAD SCIENCES, INC. (0000882095) (Filer)
144 - GILEAD SCIENCES, INC. (0000882095) (Subject)
N-PX - GILEAD SCIENCES, INC. (0000882095) (Filer)
8-K - GILEAD SCIENCES, INC. (0000882095) (Filer)
13F-HR - GILEAD SCIENCES, INC. (0000882095) (Filer)
10-Q - GILEAD SCIENCES, INC. (0000882095) (Filer)
8-K - GILEAD SCIENCES, INC. (0000882095) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Daiwa Securities upgraded Gilead Sciences from Neutral to Outperform and set a new price target of $128.00
Truist upgraded Gilead Sciences from Hold to Buy and set a new price target of $127.00
Needham upgraded Gilead Sciences from Hold to Buy and set a new price target of $133.00
Cantor Fitzgerald resumed coverage of Gilead Sciences with a rating of Overweight and set a new price target of $125.00
Oppenheimer reiterated coverage of Gilead Sciences with a rating of Outperform and set a new price target of $132.00 from $115.00 previously
Deutsche Bank upgraded Gilead Sciences from Hold to Buy and set a new price target of $120.00
DZ Bank upgraded Gilead Sciences from Hold to Buy and set a new price target of $108.00
Morgan Stanley upgraded Gilead Sciences from Equal-Weight to Overweight and set a new price target of $113.00 from $87.00 previously
BofA Securities resumed coverage of Gilead Sciences with a rating of Buy and set a new price target of $109.00
Wolfe Research initiated coverage of Gilead Sciences with a rating of Outperform and set a new price target of $110.00
Live finance-specific insights
Gilead Sciences, Inc. (NASDAQ:GILD) today announced it has been awarded the prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product for Yeztugo® (lenacapavir), the company's twice-yearly injectable HIV-1 capsid inhibitor that provides adults and adolescents (≥35kg) at risk of HIV-1 acquisition with a new, highly effective option for pre-exposure prophylaxis (PrEP) for the prevention of HIV. The award, which recognizes outstanding pharmaceutical products for their contributions to improving human health, is a testament to Gilead's long-standing commitment to HIV innovation. HIV continues to pose a formidable global health challenge, with 1.3 million new infections occurring
Product Sales Excluding Veklury Increased 4% Year-Over-Year to $7.1 billion Biktarvy Sales Increased 6% Year-Over-Year to $3.7 billion Gilead Sciences, Inc. (NASDAQ:GILD) announced today its third quarter 2025 results of operations. "We continue to deliver on Gilead's robust portfolio with a strong start for Yeztugo, rapidly growing uptake of Biktarvy, Descovy and Livdelzi, and positive data for Trodelvy in 1L metastatic triple negative breast cancer," said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. "With multiple potential product launches in 2026, the strongest clinical pipeline in Gilead's history, and no major loss of exclusivity expected until 2036, we are well-
– Additional Phase 3 PURPOSE Data Reinforce the Safety Profile of Twice-Yearly Yeztugo® as an Effective HIV Prevention Option Across Diverse Populations – – New Data Show Higher Treatment Satisfaction After Switching from IM CAB+RPV to Biktarvy® – – New Research Reaffirms Veklury® in High-Risk COVID-19 Populations and Obeldesivir in Emerging Pathogens – Gilead Sciences, Inc. (NASDAQ:GILD) will present new findings from its antiviral research and development programs at IDWeek, taking place October 19-22 in Atlanta, GA. Data from 34 presentations across HIV, respiratory viruses, viral hepatitis, and viruses of pandemic potential including six oral presentations underscore Gilead's lead
– New Data Showcase Safety Profile of Twice-Yearly Lenacapavir for Pre-Exposure Prophylaxis (PrEP) with Other Medications and Recruitment Strategies for PURPOSE 5 – – Five-Year BICSTaR Results Offer Insights into Long-Term Treatment with Biktarvy®, Helping Inform the Future of Coordinated, Person-Centered HIV Care – – Latest Results on Novel Long-Acting Combination Regimens, Including Once-Weekly and Twice-Yearly Treatment Options – Gilead Sciences, Inc. (NASDAQ:GILD) today announced its upcoming participation in the 20th European AIDS Conference (EACS) to be held in Paris, France from October 15-18. As the leader in HIV innovation, Gilead will provide an update on its strategic initi
Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its third quarter 2025 financial results and guidance will be released on Thursday, October 30, 2025 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's third quarter 2025 financial results and provide a business update. A live webcast will be available in the Investors section of www.gilead.com and will be archived there for one year. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The
– PEPFAR, Coordinated by the U.S. State Department, will Support Delivery of Lenacapavir for PrEP in High-Incidence, Resource-Limited Countries as Key Part of Strategic Efforts with Global Fund to Accelerate Access – Gilead Sciences, Inc. (NASDAQ:GILD) today announced a partnership with the U.S. State Department and the United States President's Emergency Plan for AIDS Relief (PEPFAR) to deliver lenacapavir—Gilead's twice-yearly injectable HIV-1 capsid inhibitor—for the prevention of HIV as pre-exposure prophylaxis (PrEP). This is a key component of Gilead's larger coordinated efforts, now bringing together the resources and expertise of both PEPFAR and the Global Fund, to further advance
– Yeytuo® is the First and Only European Commission (EC)-Authorized HIV PrEP Option Offering 6 Months of Protection – – Accelerated EC Decision Comes After U.S. FDA Approval in June – Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the European Commission (EC) has granted marketing authorization for Yeytuo® (lenacapavir)—the company's twice-yearly injectable HIV-1 capsid inhibitor—for use as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents with increased HIV-1 acquisition risk who weigh at least 35kg. Yeytuo is the first and only twice-yearly PrEP option to be approved for use in the European Union's 27 member states, as we
Product Sales Excluding Veklury Increased 4% Year-Over-Year to $6.9 billion Biktarvy Sales Increased 9% Year-Over-Year to $3.5 billion Gilead Sciences, Inc. (NASDAQ:GILD) announced today its second quarter 2025 results of operations. "This was a very successful second quarter for Gilead, including the FDA approval for Yeztugo as the world's first twice-yearly HIV prevention option," said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. "Our strong growth this quarter was driven by Biktarvy, Descovy, Trodelvy and Livdelzi, reflecting the diversity of our portfolio. As we enter the third quarter, we are increasing revenue and earnings guidance for the year, and look forward
– If Approved, Lenacapavir Would Be the First and Only Twice-Yearly HIV PrEP Option in the European Union – – Positive Opinion Also Received for EMA's EU-M4all Procedure, Designed to Facilitate Availability in Low- and Lower-Middle-Income Countries – Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion under accelerated review recommending lenacapavir—the company's injectable HIV-1 capsid inhibitor—for use as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents with increased HIV-1 acquisition risk. The final E
Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its second quarter 2025 financial results and guidance will be released on Thursday, August 7, 2025 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's second quarter 2025 financial results and provide a business update. A live webcast will be available in the Investors section of www.gilead.com and will be archived there for one year. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The
Live Leadership Updates
DIAMOND BAR, Calif., Oct. 21, 2025 /PRNewswire/ -- The Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL)., today announced the appointments of Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners. "I believe Carol and Mehrdad will be exceptional partners to the IFLI team and portfolio as they bring decades of strategic leadership and drug development expertise," said David McCullagh, Man
Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Timothy Watkins, M.D., M.Sc., to the Company's executive team as its Chief Medical Officer and Head of Development. Effective immediately, Dr. Watkins will lead all clinical development and medical affairs activities at Contineum. Dr. Watkins succeeds Stephen L. Huhn, M.D., who has been the Company's Chief Medical Officer since early 2020. Dr. Huhn will serve as an advisor during the leadership transition. "We're excited for D
Gilead Sciences, Inc. (NASDAQ:GILD) today announced that Dietmar Berger, MD, PhD, will join the company on January 2, 2025, as Chief Medical Officer and will become a member of Gilead's senior leadership team. Dr. Berger succeeds Merdad Parsey, MD, PhD. Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines across a broad range of therapeutic areas. He will assume responsibility for the Company's leading virology, oncology and inflammation portfolio and will oversee the company's global Development and Medical Affairs organizations. "Dietmar's exceptional leadership in
Mechelen, Belgium; 15 June 2023, 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the appointment of Thad Huston as Chief Financial Officer (CFO) and Chief Operating Officer (COO) as per 1 July 2023. Mr. Huston will be a member of the Executive Committee of Galapagos and will join Galapagos from Kite, a Gilead Company (NASDAQ:GILD). He brings 30 years of global finance and operational experience in healthcare with an excellent track record of driving business transformation and innovation. "On behalf of the Board of Directors and management of Galapagos, I extend a warm welcome to Thad. Thad is a widely recognized leader with a strong internationa
Gilead Sciences, Inc. (NASDAQ:GILD) today announced that Cindy Perettie will join the company as Executive Vice President of Kite, a Gilead Company, overseeing the cell therapy business, and will become a member of Gilead's senior leadership team, effective May 30. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230516005214/en/Gilead Appoints Cindy Perettie Executive Vice President of Kite (Photo: Business Wire) Ms. Perettie brings with her extensive experience in oncology and a commitment to improving patient care. Most recently, she was Head of Roche's Molecular Lab Solutions where she oversaw the PCR (polymerase chain reactio
MONTREAL, Nov. 29, 2022 /PRNewswire/ - Thryv Therapeutics Inc. is pleased to announce the appointment of Melissa Koomey to its Board of Directors. Ms. Koomey brings an impressive depth of experience in product commercialization, launch and marketing execution, which will be crucial as Thryv advances its development programs in rare arrhythmias such as Long QT Syndrome and advanced cancers. "We are excited to have Melissa join the Thryv Board of Directors at this pivotal time in our story. Our lead compound will emerge from initial safety studies early in 2023 and we will accelerate into efficacy trials with Melissa's experience and insights in Long QT Syndrome," said Paul F. Truex, Thryv's
– Brett Pletcher, Executive Vice President, Corporate Affairs and General Counsel to Retire After 17 Years at Gilead – Gilead Sciences, Inc. (NASDAQ:GILD) announced today that Deborah Telman will join the company as Executive Vice President, Corporate Affairs and General Counsel, and will become a member of the company's senior leadership team, reporting to Chairman and Chief Executive Officer Daniel O'Day. Ms. Telman will assume responsibility for Gilead's legal and corporate affairs function, which includes government and policy, and public affairs. Ms. Telman will start in her new role August 1, 2022. She will also become Corporate Secretary of Gilead. Ms. Telman will succeed Brett Plet
– Taiyin Yang, PhD, Executive Vice President, Pharmaceutical Development and Manufacturing to Retire After 29 Years at Gilead – Gilead Sciences, Inc. (NASDAQ:GILD) announced today that Stacey Ma, PhD will join the company as Executive Vice President, Pharmaceutical Development and Manufacturing, and will become a member of the company's senior leadership team, reporting to Chairman and Chief Executive Officer Daniel O'Day. Dr. Ma will assume responsibility for Gilead's Pharmaceutical Development and Manufacturing organization effective July 18, 2022. Dr. Ma will succeed Dr. Yang, who is retiring from Gilead after nearly three decades. Dr. Ma brings to her new role more than 25 years of ex
Eikon Therapeutics Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the appointment of Robin L. Washington as an independent director effective May 12, 2022. Ms. Washington is among the most experienced business leaders in the biopharmaceutical and technology industries, having served as Chief Financial Officer at Gilead, Inc. from 2008 until 2019, managing global finance, investor relations, facilities and operations, and information technology during a period when corporate revenue grew by more than six-fold. This press release features multimedia. View the full
Mr. Allan, the 2017 winner of the prestigious Julia Levy Award, to collaborate with 2021 Julia Levy Award winner Dr. Lakshmi P. Kotra, CEO of FSD Pharma subsidiary Lucid Psycheceuticals FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FRE: 0K9A) ("FSD Pharma" or the "Company"), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced the appointment of David Allan and John McGraw, PhD, MSc, to the Company's Advisory Board. "Mr. Allan and Dr. McGraw both have impressive careers in the field of healthcare and biotechnology underscored by tremendously successful exits and we are excited to welcome them to our team," commented Anthony Durkacz, Foun
This live feed shows all institutional transactions in real time.
SC 13G/A - GILEAD SCIENCES, INC. (0000882095) (Subject)
SC 13G/A - GILEAD SCIENCES, INC. (0000882095) (Subject)
SC 13G - GILEAD SCIENCES, INC. (0000882095) (Subject)
SC 13G/A - GILEAD SCIENCES, INC. (0000882095) (Subject)
SC 13G/A - GILEAD SCIENCES INC (0000882095) (Subject)
SC 13G/A - GILEAD SCIENCES INC (0000882095) (Subject)
SC 13G/A - GILEAD SCIENCES INC (0000882095) (Subject)
SC 13G/A - GILEAD SCIENCES INC (0000882095) (Subject)
SC 13G/A - GILEAD SCIENCES INC (0000882095) (Subject)
Live FDA approvals issued by the Food and Drug Administration and FDA breaking news
Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-6) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215973, Application Classification: Efficacy
Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-8) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215974, Application Classification: Efficacy
Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-9) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/13/2024. Application Category: NDA, Application Number: 215973, Application Classification: Manufacturing (CMC)
Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-9) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/13/2024. Application Category: NDA, Application Number: 215974, Application Classification: Labeling
Submission status for GILEAD SCIENCES INC's drug BIKTARVY (SUPPL-20) with active ingredient BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE has changed to 'Approval' on 10/08/2024. Application Category: NDA, Application Number: 210251, Application Classification: Manufacturing (CMC)
Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-7) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 07/17/2024. Application Category: NDA, Application Number: 215974, Application Classification: Labeling
Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-5) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 07/17/2024. Application Category: NDA, Application Number: 215973, Application Classification: Labeling
Submission status for GILEAD SCIENCES INC's drug VEKLURY (SUPPL-27) with active ingredient REMDESIVIR has changed to 'Approval' on 06/27/2024. Application Category: NDA, Application Number: 214787, Application Classification: Labeling
Submission status for GILEAD SCIENCES INC's drug BIKTARVY (SUPPL-19) with active ingredient BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE has changed to 'Approval' on 04/24/2024. Application Category: NDA, Application Number: 210251, Application Classification: Efficacy
Submission status for GILEAD SCIENCES INC's drug VEMLIDY (SUPPL-16) with active ingredient TENOFOVIR ALAFENAMIDE FUMARATE has changed to 'Approval' on 03/27/2024. Application Category: NDA, Application Number: 208464, Application Classification: Efficacy